Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RANI Rani Therapeutics Holdings

Market Closed 04-17 16:00:00 EDT

1.17

+0.02

+1.74%

盘后1.13

-0.04-3.42%

19:41 EDT

High1.20	Low1.11	Vol67.76K
Open1.17	D1 Closing1.15	Amplitude7.83%
Mkt Cap39.21M	Tradable Cap27.48M	Total Shares33.51M
T/O76.94K	T/O Rate0.29%	Tradable Shares23.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"RANI","market":"US","secType":"STK","nameCN":"Rani Therapeutics Holdings","latestPrice":1.17,"timestamp":1744920000000,"preClose":1.15,"halted":0,"volume":67759,"hourTrading":{"tag":"盘后","latestPrice":1.13,"preClose":1.17,"latestTime":"19:41 EDT","volume":598,"amount":692.27,"timestamp":1744933278374},"delay":0,"floatShares":23487520,"shares":33509827,"eps":-1.05415,"marketStatus":"Market Closed","change":0.02,"latestTime":"04-17 16:00:00 EDT","open":1.17,"high":1.2,"low":1.11,"amount":76944.139004,"amplitude":0.078261,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.05415,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":1.15,"preHourTrading":{"tag":"盘前","latestPrice":1.2,"preClose":1.15,"latestTime":"08:20 EDT","volume":127,"amount":150.5200063,"timestamp":1744892436968},"postHourTrading":{"tag":"盘后","latestPrice":1.13,"preClose":1.17,"latestTime":"19:41 EDT","volume":598,"amount":692.27,"timestamp":1744933278374},"volumeRatio":0.7456245860921338,"impliedVol":0.0559,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/RANI","defaultTab":"news","newsList":[{"id":"2524230649","title":"Rani Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524230649","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524230649?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 19:07","pubTimestamp":1743678420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RANI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 07:07 ET (11:07 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","RANI"],"gpt_icon":0},{"id":"2524234962","title":"Rani Therapeutics Holdings: Buy Rating Backed by Strong Financial Position and Promising Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2524234962","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524234962?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 18:17","pubTimestamp":1743675423,"startTime":"0","endTime":"0","summary":"Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Rani Therapeutics Holdings (RANI – Research Report), retaining the price targ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/rani-therapeutics-holdings-buy-rating-backed-by-strong-financial-position-and-promising-clinical-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/rani-therapeutics-holdings-buy-rating-backed-by-strong-financial-position-and-promising-clinical-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI"],"gpt_icon":0},{"id":"2524126229","title":"RANI: 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524126229","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524126229?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 23:31","pubTimestamp":1743521460,"startTime":"0","endTime":"0","summary":"On March 31st, Rani Therapeutics Holdings, Inc.  reported 2024 results. Since the third quarter report, Rani has participated in multiple investor conferences, raised an additional $10 million and reported glucagon-like peptide-1 receptor  incretin triagonist data. Most importantly, Rani’s lead program, RT-114, produced favorable preclinical data demonstrating superior bioavailability compared to the underlying molecule’s subcutaneous results. In parallel, partner ProGen provided an update on their Phase I trial for PG-102 which is in the vanguard for the GLP-1/GLP-2 dual agonist program. The other significant area of interest is an anticipated deal with an established biopharmaceutical company which may include upfronts, milestones and royalties for Rani. In this vein, Rani conducted testing on behalf of an unnamed but significant biopharma, receiving $1.0 million in contract revenue and germinating a prospect in the process.Research and development expenses totaled $26.7 million, dow","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rani-2024-financial-results-153100664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","LU1868837300.USD","LU0323591593.USD","LU1066053197.SGD","LU2129689605.HKD","BK4541","BK4534","LU1162221912.USD","LU1066051498.USD","LU2552382058.USD","LU0096364046.USD","LU0098860793.USD","BK4018","SG9999014567.USD","IE00BWXC8680.SGD","LU0689626769.HKD","LU0094547139.USD","RANI","LU0061475181.USD","LU0640476718.USD","BK4550","LU0823414478.USD","SG9999002224.SGD","LU0237698245.USD","LU1430594728.SGD","SG9999014542.SGD","BK4585","LU1868837136.USD","BK4559","SG9999001440.SGD","LU1720051017.SGD","BK4588","BK4567","LU2552382132.HKD","BK4533","LU2129689431.USD","LU0234570918.USD","LU2242652126.USD","IE00BLSP4452.SGD","PG","LU1914381329.SGD","LU0124676726.USD","PLUG","SG9999014575.USD","IE000M9KFDE8.USD","LU2129689514.USD","SG9999015341.SGD","IE00B3T34201.USD","BK4504","SG9999002232.USD"],"gpt_icon":0},{"id":"2524118633","title":"Stifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524118633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524118633?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:56","pubTimestamp":1743508601,"startTime":"0","endTime":"0","summary":"In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Rani Therapeutics Holdings (RANI – Research Report), wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-rani-therapeutics-holdings-rani-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-rani-therapeutics-holdings-rani-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI","SF"],"gpt_icon":0},{"id":"2524821154","title":"Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Highlights: Navigating Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2524821154","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524821154?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 15:05","pubTimestamp":1743491110,"startTime":"0","endTime":"0","summary":"Cash, Cash Equivalents, and Marketable Securities: $27.6 million as of December 31, 2024, compared to $48.5 million as of December 31, 2023.Contract Revenue: Approximately $1 million for the fourth quarter and full year 2024, with no contract revenue for the same period in 2023.Research and Development Expenses: $6.8 million for Q4 2024 and $26.7 million for the full year 2024, compared to $7.6 million and $39.6 million for the same periods in 2023.General and Administrative Expenses: $5.5 million for Q4 2024 and $23.9 million for the full year 2024, compared to $5.8 million and $26.5 million for the same periods in 2023.Impairment Loss: $3.7 million related to certain manufacturing property and equipment in 2024, with no such losses in 2023.Net Loss: $15.7 million for Q4 2024 and $56.6 million for the full year 2024, compared to $14.1 million and $67.9 million for the same periods in 2023.Stock-Based Compensation Expense: $4 million for Q4 2024 and $16 million for the full year 2024, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rani-therapeutics-holdings-inc-rani-070510778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RANI"],"gpt_icon":0},{"id":"2524906481","title":"BRIEF-Rani Therapeutics Q4 Operating Expenses USD 15.986 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2524906481","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524906481?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 06:43","pubTimestamp":1743461009,"startTime":"0","endTime":"0","summary":"BRIEF-Rani Therapeutics Q4 Operating Expenses USD 15.986 MillionMarch 31 (Reuters) - Rani Therapeutics Holdings Inc RANI.O:RANI THERAPEUTICS Q4 OPERATING EXPENSES USD 15.986 MILLIONRANI THERAPEUTICS Q","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nPLX769C86:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI"],"gpt_icon":0},{"id":"2524970922","title":"Rani Therapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524970922","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524970922?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 05:00","pubTimestamp":1743454857,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings SummaryRani Therapeutics Holdings Inc RANI.OQ reported a quarterly adjusted loss of 27 cents per share for t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL5N3QE1OQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI"],"gpt_icon":0},{"id":"2524974956","title":"Rani Therapeutics Hldgs Q4 2024 GAAP EPS $(0.27) Misses $(0.25) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2524974956","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524974956?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 04:07","pubTimestamp":1743451649,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.25) by 8 percent. This is unchanged from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44570896/rani-therapeutics-hldgs-q4-2024-gaap-eps-0-27-misses-0-25-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","LENZ"],"gpt_icon":0},{"id":"2524974150","title":"Rani Therapeutics Q4 Operating Expenses USD 15.986 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2524974150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524974150?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 04:05","pubTimestamp":1743451500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nPLX769C86:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4539","RANI"],"gpt_icon":0},{"id":"2524972487","title":"Rani Therapeutics Holdings Inc  Q4 Shr View $-0.25 -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2524972487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524972487?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 04:05","pubTimestamp":1743451500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nPLX769C86:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4007","RANI"],"gpt_icon":0},{"id":"2524972485","title":"Rani Therapeutics Holdings Inc Q4 Shr Loss $0.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2524972485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524972485?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 04:05","pubTimestamp":1743451500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nPLX769C86:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4539","RANI"],"gpt_icon":0},{"id":"2524972120","title":"Rani Therapeutics Holdings: Cash, Cash Equivalents & Marketable Securities Sufficient to Fund Ops Into Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2524972120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524972120?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 04:05","pubTimestamp":1743451500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nPLX769C86:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RANI","BK4539"],"gpt_icon":0},{"id":"2524974695","title":"Press Release: Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524974695","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524974695?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 04:05","pubTimestamp":1743451500,"startTime":"0","endTime":"0","summary":"- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist  delivered orally via the RaniPill capsule, to subcutaneous administration of PG-102 -. - Preclinical data of four incretin-based molecules underscores the RaniPill platform's potential to facilitate the oral delivery of a diverse array of obesity treatments -. - Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 -. - Conference call today at 4:30 p.m. ET / 1:30 p.m. PT -. SAN JOSE, Calif., March 31, 2025  -- Rani Therapeutics Holdings, Inc.  , a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2024 and provided a corporate update.-- Positive topline results from phase 1 study of an oral anti-interleukin. 12/23 antibody . In February 2024, Rani announced RT-111 achieved. high bioavailability and was well tolerated, with no serio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014567.USD","PG","BK4559","SG9999002232.USD","LU0323591593.USD","R","LU0237698245.USD","LU1868836591.USD","BK4022","BK4534","BK4139","BK4558","BK4585","LU2552382215.SGD","BK4007","SG9999002224.SGD","BK4581","LU1868837136.USD","BK4018","LU1868837300.USD","BK4533","IE00B1XK9C88.USD","SG9999015341.SGD","LU2552382058.USD","LENZ","LU1868836757.USD","LU2552382132.HKD","LU2242652126.USD","LU2129689514.USD","LU2129689605.HKD","BK4550","LU0640476718.USD","LU1929549753.HKD","IE00BBT3K403.USD","LU0061475181.USD","LU0098860793.USD","IE00BWXC8680.SGD","RANI","LU2129689431.USD","SG9999015358.SGD","LU1162221912.USD","LU0096364046.USD","LU1066053197.SGD","SG9999001440.SGD","IE00BLSP4239.USD","BK4567","IE000M9KFDE8.USD","LU0689626769.HKD","SG9999014575.USD","SG9999014542.SGD"],"gpt_icon":0},{"id":"2523915166","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2523915166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523915166?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 18:00","pubTimestamp":1743415200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FC","BK4023","APOG","BK4524","CELC","BW","MSM","PRGS","REKR","GWH","SPIR","CAG","RDUS","LW","RH","BK4178","BK4141","LNN","UNF","AYI","OMER","SGML","SLP","BK4584","NNOX","LU0054578231.USD","BK4200","PVH","TTGT","BHST","AMC","WPRT","PENG","LOAR","ANGO","BK4007","LPRO","FTCI","BLRX","CUK","LNZA","PVLA","RANI","SPWH","NCNO","PROK","BK4167","BK4086","DARE"],"gpt_icon":0},{"id":"2522329609","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329609?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.55)  4:05 PM. ·TD SYNNEX Corp                                   1Q      2.91   8:05 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI","PENG","INR","WKSP","LULU","NCNO","ADCT","KYTX","WBA","CRDL","BW","INMB","PVLA","SKYH","UNCY","FBIO","RANI","BLRX","REKR","DARE","SDST","IKT","LNZA","WGO","SPWH","FC","TSAT","RLMD","NNOX","TLSI","BHST","GWH","EDAP","BCAB","SGML","GOVX","FTCI","MDAI","FEMY","BRZE","NUTX","ANGO","CELC","CLSD","PVH","GEVO","AFMD","PRGS","SLRN","CALC"],"gpt_icon":0},{"id":"2522215330","title":"BRIEF-Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered PG-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2522215330","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522215330?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:10","pubTimestamp":1743019828,"startTime":"0","endTime":"0","summary":"BRIEF-Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI"],"gpt_icon":0},{"id":"2522304953","title":"Rani Therapeutics Holdings Inc  expected to post a loss of 25 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522304953","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522304953?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:07","pubTimestamp":1743019675,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc  expected to post a loss of25cents a share - Earnings Preview Rani Therapeutics Holdings Inc RANI.OQ RANI.O is expected to show no change in quarterly revenue when it re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL5N3Q9230:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI"],"gpt_icon":0},{"id":"2522733017","title":"Rani Therapeutics Holdings: Phase 1 Clinical Study for Rt-114 for Treatment of Obesity Expected to Initiate in Mid- 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522733017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522733017?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90ZF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RANI","BK4007"],"gpt_icon":0},{"id":"2522330159","title":"Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of Rt-114, a Glp-1/Glp-2 Dual Agonist (Pg-102) Delivered Orally via the Ranipill® Capsule, to Subcutaneously Administered Pg-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2522330159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522330159?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4007","BK4539"],"gpt_icon":0},{"id":"2522581083","title":"Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2522581083","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522581083?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":"-  RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence –。- Both groups demonstrated comparable weight loss with less variability observed with RT-114 compared to subcutaneous PG-102 –。- Phase 1 clinical trial of subcutaneous PG-102 demonstrated weight loss in obese patients, with an average reduction of 4.8% and up to 8.7% following five weeks of dosing -. - Data bolster expanding body of evidence of the RaniPill platform’s potential to facilitate oral delivery of multiple obesity treatments including previously announced semaglutide -. - Phase 1 clinical study for RT-114 for the treatment of obesity expected to initiate in mid- 2025 -. ProGen recently announced preliminary results of the repeat-dose portion  of its Phase 1 study where SC PG-102 demonstrated weight loss in obese subjects, with an average reduction of 4.8% and up to 8.7% following five week","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rani-therapeutics-announces-preclinical-data-200500857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","PG","LENZ","RANI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ranitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":-0.22},{"period":"3month","weight":-0.1069},{"period":"6month","weight":-0.5634},{"period":"1year","weight":-0.851},{"period":"ytd","weight":-0.146}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.063792},{"month":2,"riseRate":0.75,"avgChangeRate":0.033575},{"month":3,"riseRate":0,"avgChangeRate":-0.179251},{"month":4,"riseRate":0.25,"avgChangeRate":0.199199},{"month":5,"riseRate":0,"avgChangeRate":-0.112571},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.131049},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.042456},{"month":8,"riseRate":0.5,"avgChangeRate":0.121517},{"month":9,"riseRate":0.25,"avgChangeRate":-0.177463},{"month":10,"riseRate":0.5,"avgChangeRate":-0.027809},{"month":11,"riseRate":0.75,"avgChangeRate":0.134593},{"month":12,"riseRate":0.25,"avgChangeRate":-0.095209}],"exchange":"NASDAQ","name":"Rani Therapeutics Holdings","nameEN":"Rani Therapeutics Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rani Therapeutics Holdings(RANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rani Therapeutics Holdings,RANI,Rani Therapeutics Holdings股票,Rani Therapeutics Holdings股票老虎,Rani Therapeutics Holdings股票老虎国际,Rani Therapeutics Holdings行情,Rani Therapeutics Holdings股票行情,Rani Therapeutics Holdings股价,Rani Therapeutics Holdings股市,Rani Therapeutics Holdings股票价格,Rani Therapeutics Holdings股票交易,Rani Therapeutics Holdings股票购买,Rani Therapeutics Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rani Therapeutics Holdings(RANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction